Related references
Note: Only part of the references are listed.Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients
Xi Yang et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
Bhagirathbhai Dholaria et al.
HAEMATOLOGICA (2020)
Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation
Pier Edoardo Rovatti et al.
FRONTIERS IN IMMUNOLOGY (2020)
Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3-AKT-P21-CDK2 signaling pathway
Hao Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells
Wei Zhang et al.
CANCER MEDICINE (2019)
Low-dose chidamide restores immune tolerance in ITP in mice and humans
Hong-yu Zhao et al.
BLOOD (2019)
Relapse and Survival After Transplantation for Complex Karyotype Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and The University of Texas MD Anderson Cancer Center
Stefan O. Ciurea et al.
CANCER (2018)
Donor lymphocyte infusion in myeloid disorders
Selami Kocak Toprak
TRANSFUSION AND APHERESIS SCIENCE (2018)
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse
Mohamed A. Kharfan-Dabaja et al.
JAMA ONCOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy
Y. Lun et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine
Xia Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
Donor lymphocyte infusion after allogeneic stem cell transplantation
Luca Castagna et al.
TRANSFUSION AND APHERESIS SCIENCE (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
Nelli Bejanyan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans
Sung Won Choi et al.
BLOOD (2015)
Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
Yushi Yao et al.
PLOS ONE (2013)
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
Zhi-Qiang Ning et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
Guoqing Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation.
Luca Vago et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
P Reddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)